Organon & Co.(OGN)Earnings, Financials & Key Ratios

OGN•NYSE

$13.41

$3.49B mkt cap·18.6× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryGenerics and biosimilars manufacturers

AboutOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.Show more

Revenue$6.22B-2.9%
EBITDA$1.64B-7.1%
Net Income$187M-78.4%
EPS (Diluted)0.72-78.4%
Gross Margin54.09%-6.8%
EBITDA Margin26.36%-4.3%
Operating Margin20.67%-10.9%
Net Margin3.01%-77.7%
ROE27.14%-93.7%
ROIC19.79%+51.0%
Interest Coverage2.55-10.8%

Technical→

OGN Key Insights

Organon & Co. (OGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 228.5%
✓Momentum leader: RS Rating 92 (top 8%)
✓Healthy 5Y average net margin of 13.8%
✓Trading near 52-week high

✗Weaknesses

✗Profits declining 38.7% over 5 years
✗Weak Piotroski F-Score: 0/9
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

OGN Price & Volume

Organon & Co. (OGN) stock price & volume — 10-year historical chart

Loading chart...

OGN Growth Metrics

Organon & Co. (OGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-0.99%

3 Years0.23%

TTM-2.92%

Profit CAGR

10 Years-

5 Years-38.7%

3 Years-41.14%

TTM-78.36%

EPS CAGR

10 Years-

5 Years-38.99%

3 Years-41.47%

TTM-78.68%

Return on Capital

10 Years25.28%

5 Years19.08%

3 Years16.7%

Last Year19.79%

OGN Recent Earnings

Organon & Co. (OGN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)

Q1 2026Latest

Feb 12, 2026

EPS

$0.63

Est $0.73

-13.7%

Revenue

$1.5B

Est $1.5B

-1.8%

Q4 2025

Nov 10, 2025

EPS

$1.01

Est $0.93

+8.6%

Revenue

$1.6B

Est $1.5B

+5.3%

Q3 2025

Aug 5, 2025

EPS

$1.00

Est $0.94

+6.4%

Revenue

$1.6B

Est $1.6B

+2.1%

Q2 2025

May 1, 2025

EPS

$1.02

Est $0.89

+14.6%

Revenue

$1.5B

Est $1.5B

-1.5%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 12, 2026	$0.63vs $0.73-13.7%	$1.5Bvs $1.5B-1.8%
Q4 2025	Nov 10, 2025	$1.01vs $0.93+8.6%	$1.6Bvs $1.5B+5.3%
Q3 2025	Aug 5, 2025	$1.00vs $0.94+6.4%	$1.6Bvs $1.6B+2.1%
Q2 2025	May 1, 2025	$1.02vs $0.89+14.6%	$1.5Bvs $1.5B-1.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
PFEPfizer Inc.Direct Competitor	150.77B	26.51	19.49	-1.65%	11.83%	8.34%	0.78
VTRSViatris Inc.Direct Competitor	18.37B	15.95	-5.32	-2.98%	-24.58%	-23.89%	0.98
ABBVAbbVie Inc.Direct Competitor	362.56B	204.98	86.49	8.57%	6.91%	62.15%
HLNHaleon plcDirect Competitor	41.1B	9.23	18.87	-3.96%	14.46%	19.9%	0.52
TEVATeva Pharmaceutical Industries LimitedProduct Competitor	42.31B	36.34	30.28	4.31%	9.02%	20.69%	2.20
PRGOPerrigo Company plcProduct Competitor	1.69B	12.26	-1.19	-2.75%	-43.5%	-50.65%	1.35
EVAXEvaxion Biotech A/SProduct Competitor	4.73M	4.41	-0.45	44.81%	-70.87%	-68.86%
ANIPANI Pharmaceuticals, Inc.Product Competitor	1.78B	84.06	25.32	43.78%	8.87%	14.49%	0.60

Compare OGN vs Peers

Organon & Co. (OGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PFE

Most directly comparable listed peer for OGN.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare OGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs PFE, VTRS, ABBV, HLN

OGN Income Statement

Organon & Co. (OGN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	9.78B	7.78B	6.53B	6.3B	6.17B	6.26B	6.4B	6.22B
Revenue Growth %	-	-20.46%	-16.01%	-3.49%	-2.06%	1.44%	2.24%	-2.92%
Cost of Goods Sold	4.69B	2.27B	2.12B	2.38B	2.29B	2.52B	2.69B	2.85B
COGS % of Revenue	48%	29.24%	32.44%	37.79%	37.16%	40.16%	41.98%	45.91%
Gross Profit	5.08B▲ 0%	5.5B▲ 8.2%	4.41B▼ 19.8%	3.92B▼ 11.1%	3.88B▼ 1.1%	3.75B▼ 3.4%	3.71B▼ 0.9%	3.36B▼ 9.5%
Gross Margin %	52%	70.76%	67.56%	62.21%	62.84%	59.84%	58.02%	54.09%
Gross Profit Growth %	-	8.24%	-19.81%	-11.13%	-1.07%	-3.4%	-0.88%	-9.5%
Operating Expenses	2.38B	1.66B	1.57B	2.01B	2.17B	2.42B	2.23B	2.09B
OpEx % of Revenue	24.32%	21.38%	23.97%	31.84%	35.23%	38.66%	34.81%	33.57%
Selling, General & Admin	2.01B	1.44B	1.36B	1.67B	1.7B	1.89B	1.76B	1.71B
SG&A % of Revenue	20.59%	18.55%	20.76%	26.46%	27.6%	30.23%	27.49%	27.53%
Research & Development	365M	220M	210M	443M	471M	528M	469M	366M
R&D % of Revenue	3.73%	2.83%	3.21%	7.03%	7.63%	8.43%	7.32%	5.89%
Other Operating Expenses	0	0	0	-104M	0	0	0	10M
Operating Income	2.71B▲ 0%	3.85B▲ 42.2%	2.85B▼ 26.0%	1.92B▼ 32.7%	1.71B▼ 11.0%	1.33B▼ 22.2%	1.49B▲ 12.0%	1.28B▼ 13.5%
Operating Margin %	27.68%	49.47%	43.59%	30.38%	27.62%	21.19%	23.21%	20.67%
Operating Income Growth %	-	42.17%	-25.99%	-32.74%	-10.97%	-22.17%	11.98%	-13.53%
EBITDA	4.38B	4.2B	2.99B	2.11B	1.92B	1.56B	1.76B	1.64B
EBITDA Margin %	44.79%	54.02%	45.76%	33.47%	31.05%	24.96%	27.53%	26.36%
EBITDA Growth %	-	-4.06%	-28.85%	-29.41%	-9.15%	-18.47%	12.8%	-7.07%
D&A (Non-Cash Add-back)	1.67B	354M	142M	195M	212M	236M	277M	353.33M
EBIT	2.71B	3.56B	2.85B	1.79B	1.54B	1.2B	1.33B	1.28B
Net Interest Income	0	13M	-6M	-258M	-422M	-527M	-520M	-504M
Interest Income	0	19M	0	0	0	0	0	0
Interest Expense	0	6M	6M	258M	422M	527M	520M	504M
Other Income/Expense	23M	-144M	-95M	-386M	-583M	-654M	-679M	-860M
Pretax Income	2.73B▲ 0%	3.7B▲ 35.4%	2.75B▼ 25.5%	1.53B▼ 44.4%	1.12B▼ 26.6%	673M▼ 40.0%	807M▲ 19.9%	425M▼ 47.3%
Pretax Margin %	27.91%	47.52%	42.13%	24.25%	18.17%	10.75%	12.6%	6.84%
Income Tax	576M	390M	496M	178M	205M	-350M	-57M	238M
Effective Tax Rate %	21.11%	10.55%	18.02%	11.64%	18.27%	-52.01%	-7.06%	56%
Net Income	2.15B▲ 0%	3.22B▲ 49.5%	2.16B▼ 32.9%	1.35B▼ 37.5%	917M▼ 32.1%	1.02B▲ 11.6%	864M▼ 15.5%	187M▼ 78.4%
Net Margin %	22.02%	41.38%	33.07%	21.43%	14.85%	16.33%	13.49%	3.01%
Net Income Growth %	-	49.47%	-32.88%	-37.45%	-32.12%	11.56%	-15.54%	-78.36%
Net Income (Continuing)	2.15B	3.31B	2.26B	1.35B	917M	1.02B	864M	187M
Discontinued Operations	0	0	-96M	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)	8.51▲ 0%	12.71▲ 49.4%	8.52▼ 33.0%	5.33▼ 37.4%	3.59▼ 32.6%	3.99▲ 11.1%	3.33▼ 16.5%	0.72▼ 78.4%
EPS Growth %	-	49.35%	-32.97%	-37.44%	-32.65%	11.14%	-16.54%	-78.38%
EPS (Basic)	8.51	12.71	8.52	5.33	3.61	4.01	3.36	0.72
Diluted Shares Outstanding	253.13M	253.13M	253.52M	253.55M	255.17M	256.27M	259.15M	260.76M
Basic Shares Outstanding	253.13M	253.13M	253.52M	253.55M	254.08M	255.24M	257.05M	259.5M
Dividend Payout Ratio	-	-	-	10.73%	31.62%	28.74%	34.38%	-

OGN Balance Sheet

Organon & Co. (OGN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	3.71B	3.96B	3.57B	3.76B	3.93B	4.51B	4.35B	0
Cash & Short-Term Investments	244M	319M	12M	737M	706M	693M	675M	672M
Cash Only	244M	319M	12M	737M	706M	693M	675M	0
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	1.59B	1.57B	1.41B	1.51B	1.61B	1.86B	1.49B	0
Days Sales Outstanding	59.47	73.83	78.51	87.54	94.94	108.22	84.99	-
Inventory	994M	1.07B	913M	915M	1B	1.31B	1.32B	0
Days Inventory Outstanding	77.31	171.91	157.27	140.21	159.59	190.84	179.38	-
Other Current Assets	883M	992M	1.24B	596M	616M	643M	861M	-672M
Total Non-Current Assets	6.78B	6.59B	6.54B	6.92B	7.02B	7.55B	8.75B	0
Property, Plant & Equipment	651M	762M	1.01B	1.2B	1.23B	1.36B	1.32B	0
Fixed Asset Turnover	15.02x	10.21x	6.44x	5.24x	5.01x	4.62x	4.83x	-
Goodwill	4.6B	4.6B	4.6B	4.6B	4.6B	4.6B	4.68B	0
Intangible Assets	812M	569M	503M	651M	649M	533M	1.41B	0
Long-Term Investments	0	0	0	0	0	0	27M	0
Other Non-Current Assets	714M	659M	421M	464M	272M	250M	361M	0
Total Assets	10.49B▲ 0%	10.55B▲ 0.5%	10.11B▼ 4.2%	10.68B▲ 5.7%	10.96B▲ 2.6%	12.06B▲ 10.1%	13.1B▲ 8.6%	0▼ 100.0%
Asset Turnover	0.93x	0.74x	0.65x	0.59x	0.56x	0.52x	0.49x	-
Asset Growth %	-	0.51%	-4.16%	5.66%	2.57%	10.07%	8.65%	-100%
Total Current Liabilities	1.54B	1.34B	2.67B	2.6B	2.51B	2.92B	2.72B	0
Accounts Payable	289M	258M	259M	1.38B	1.13B	1.31B	1.15B	0
Days Payables Outstanding	22.48	41.41	44.61	211.77	180.11	190.7	156.56	-
Short-Term Debt	115M	48M	8M	55M	57M	55M	64M	0
Deferred Revenue (Current)	322M	0	0	0	0	0	0	0
Other Current Liabilities	6M	793M	2.12B	975M	1.14B	1.34B	1.37B	0
Current Ratio	2.40x	2.95x	1.33x	1.45x	1.56x	1.54x	1.60x	-
Quick Ratio	1.76x	2.15x	0.99x	1.10x	1.17x	1.09x	1.11x	-
Cash Conversion Cycle	114.3	204.32	191.16	15.98	74.42	108.37	107.81	-
Total Non-Current Liabilities	2.6B	2.17B	1.95B	9.59B	9.34B	9.21B	9.91B	-906M
Long-Term Debt	34M	70M	0	9.13B	8.9B	8.75B	8.86B	0
Capital Lease Obligations	0	68M	23M	184M	150M	125M	112M	0
Deferred Tax Liabilities	149M	139M	128M	4M	19M	47M	74M	0
Other Non-Current Liabilities	2.57B	1.9B	1.8B	279M	261M	287M	865M	-906M
Total Liabilities	4.15B	3.51B	4.62B	12.19B	11.85B	12.13B	12.63B	-906M
Total Debt	149M	186M	31M	9.36B	9.11B	8.93B	9.04B	0
Net Debt	-95M	-133M	19M	8.63B	8.41B	8.24B	8.36B	0
Debt / Equity	0.02x	0.03x	0.01x	-	-	-	19.14x	-
Debt / EBITDA	0.03x	0.04x	0.01x	4.44x	4.75x	5.71x	5.13x	-
Net Debt / EBITDA	-0.02x	-0.03x	0.01x	4.09x	4.38x	5.27x	4.74x	-
Interest Coverage	-	641.17x	474.50x	7.42x	4.04x	2.52x	2.86x	2.55x
Total Equity	6.35B▲ 0%	7.04B▲ 10.8%	5.49B▼ 22.0%	-1.51B▼ 127.5%	-892M▲ 40.8%	-70M▲ 92.2%	472M▲ 774.3%	906M▲ 91.9%
Equity Growth %	-	10.82%	-22.02%	-127.49%	40.85%	92.15%	774.29%	91.95%
Book Value per Share	25.08	27.79	21.64	-5.95	-3.50	-0.27	1.82	3.47
Total Shareholders' Equity	6.35B	7.04B	5.49B	-1.51B	-892M	-70M	472M	906M
Common Stock	7.26B	7.95B	6.11B	3M	3M	3M	3M	0
Retained Earnings	0	0	0	-998M	-331M	443M	1.01B	0
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-908M	-914M	-622M	-513M	-564M	-541M	-649M	906M
Minority Interest	0	0	0	0	0	0	0	0

OGN Cash Flow Statement

Organon & Co. (OGN) cash flow — operating, investing & free cash flow history

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	3.69B	2.77B	2.19B	2.46B	858M	799M	939M	0
Operating CF Margin %	37.71%	35.58%	33.48%	38.99%	13.9%	12.76%	14.67%	-
Operating CF Growth %	-	-24.95%	-20.96%	12.39%	-65.09%	-6.88%	17.52%	-100%
Net Income	2.15B	3.31B	2.26B	1.35B	917M	1.02B	864M	187M
Depreciation & Amortization	1.67B	333M	142M	195M	212M	236M	277M	0
Stock-Based Compensation	56M	41M	40M	59M	75M	101M	105M	77M
Deferred Taxes	37M	12M	-32M	-288M	-18M	-485M	-160M	0
Other Non-Cash Items	-58M	-253M	-22M	439M	124M	79M	131M	-264M
Working Capital Changes	-174M	-672M	-197M	702M	-452M	-155M	-278M	0
Change in Receivables	250M	200M	159M	-277M	-123M	-212M	383M	0
Change in Inventory	44M	-91M	-29M	-138M	-220M	-230M	-131M	0
Change in Payables	20M	-35M	27M	663M	-237M	163M	-157M	0
Cash from Investing	-69M	-102M	-258M	-481M	-420M	-260M	-513M	0
Capital Expenditures	-101M	-92M	-278M	-488M	-427M	-259M	-351M	0
CapEx % of Revenue	1.03%	1.18%	4.26%	7.74%	6.92%	4.14%	5.48%	-
Acquisitions	32M	7M	5M	-185M	-124M	-2M	-166M	0
Investments	-	-	-	-	-	-	-	-
Other Investing	32M	-17M	15M	192M	131M	1M	4M	0
Cash from Financing	-4.16B	-2.62B	-2.17B	-1.33B	-433M	-569M	-368M	0
Debt Issued (Net)	59M	0	1.51B	7.85B	-108M	-258M	-11M	0
Equity Issued (Net)	0	0	0	0	-1000K	-1000K	-1000K	0
Dividends Paid	0	0	0	-145M	-290M	-294M	-297M	0
Share Repurchases	0	0	0	0	-11M	-17M	-22M	0
Other Financing	-4.22B	-2.62B	-3.69B	-9.03B	-24M	0	-38M	0
Net Change in Cash	-527M▲ 0%	75M▲ 114.2%	-249M▼ 432.0%	667M▲ 367.9%	-31M▼ 104.6%	-13M▲ 58.1%	-18M▼ 38.5%	-675M▼ 3650.0%
Free Cash Flow	3.59B▲ 0%	2.67B▼ 25.4%	1.91B▼ 28.6%	1.97B▲ 3.2%	431M▼ 78.1%	538M▲ 24.8%	588M▲ 9.3%	0▼ 100.0%
FCF Margin %	36.68%	34.4%	29.23%	31.25%	6.98%	8.59%	9.18%	-
FCF Growth %	-	-25.4%	-28.64%	3.2%	-78.12%	24.83%	9.29%	-100%
FCF per Share	14.17	10.57	7.53	7.77	1.69	2.10	2.27	-
FCF Conversion (FCF/Net Income)	1.71x	0.86x	1.01x	1.82x	0.94x	0.78x	1.09x	-
Interest Paid	0	0	0	0	0	495M	0	0
Taxes Paid	0	0	0	0	0	0	0	0

OGN Key Ratios

Organon & Co. (OGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	33.92%	48.09%	34.5%	67.92%	-	-	429.85%	27.14%
Return on Invested Capital (ROIC)	32.46%	43.87%	34.42%	22.75%	17.48%	12.69%	13.11%	19.79%
Gross Margin	52%	70.76%	67.56%	62.21%	62.84%	59.84%	58.02%	54.09%
Net Margin	22.02%	41.38%	33.07%	21.43%	14.85%	16.33%	13.49%	3.01%
Debt / Equity	0.02x	0.03x	0.01x	-	-	-	19.14x	-
Interest Coverage	-	641.17x	474.50x	7.42x	4.04x	2.52x	2.86x	2.55x
FCF Conversion	1.71x	0.86x	1.01x	1.82x	0.94x	0.78x	1.09x	-
Revenue Growth	-	-20.46%	-16.01%	-3.49%	-2.06%	1.44%	2.24%	-2.92%

OGN SEC Filings & Documents

Organon & Co. (OGN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Feb 20, 2026·SEC

Material company update

Feb 12, 2026·SEC

Material company update

Nov 10, 2025·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 28, 2025·SEC

FY 2024

Feb 26, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 6, 2025·SEC

FY 2025

May 2, 2025·SEC

OGN Frequently Asked Questions

Organon & Co. (OGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Organon & Co. (OGN) reported $6.22B in revenue for fiscal year 2025. This represents a 36% decrease from $9.78B in 2018.

Organon & Co. (OGN) saw revenue decline by 2.9% over the past year.

Yes, Organon & Co. (OGN) is profitable, generating $187.0M in net income for fiscal year 2025 (3.0% net margin).

Dividend & Returns

Organon & Co. (OGN) has a return on equity (ROE) of 27.1%. This is excellent, indicating efficient use of shareholder capital.

Organon & Co. (OGN) generated $308.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More OGN

Organon & Co. (OGN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Organon & Co.(OGN)Earnings, Financials & Key Ratios

OGN Key Insights

✓Strengths

✗Weaknesses

OGN Price & Volume

OGN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

OGN Recent Earnings

OGN Peer Comparison

Compare OGN vs Peers

vs PFE

vs ABBV

Compare Top 5

OGN Income Statement

OGN Balance Sheet

OGN Cash Flow Statement

OGN Key Ratios

OGN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

OGN Frequently Asked Questions

Explore More OGN

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation